Long-acting lenacapavir protects macaques against intravenous challenge with simian-tropic HIVResearch in context

Long-acting lenacapavir protects macaques against intravenous challenge with simian-tropic HIVResearch in context

Summary: Background: Long-acting subcutaneous lenacapavir (LEN), a first-in-class HIV capsid inhibitor approved by the US FDA for the treatment of multidrug-resistant HIV-1 with twice yearly dosing, is under investigation for HIV-1 pre-exposure prophylaxis (PrEP). We previously derived a simian-tro...

Full description

Bibliographic Details
Main Authors: Adrienne E. Swanstrom, Robert J. Gorelick, Jorden L. Welker, Fabian Schmidt, Bing Lu, Kelly Wang, William Rowe, Matthew W. Breed, Kristin E. Killoran, Joshua A. Kramer, Duncan Donohue, James D. Roser, Paul D. Bieniasz, Theodora Hatziioannou, Cathi Pyle, James A. Thomas, Charles M. Trubey, Jim Zheng, Wade Blair, Stephen R. Yant, Jeffrey D. Lifson, Gregory Q. Del Prete
Format: Article
Language:English
Published: Elsevier 2023-09-01
Series:EBioMedicine
Subjects:
HIV
Pre-exposure prophylaxis
PrEP
Nonhuman primate
Macaque
Capsid
Online Access:http://www.sciencedirect.com/science/article/pii/S2352396423003304

Internet

http://www.sciencedirect.com/science/article/pii/S2352396423003304

Similar Items